Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.
Computer modeling of real patient data identifies which individuals will respond best to CAR-T therapy, potentially guiding dose and patient selection.
Quantitative systems pharmacology model of MM CAR-T dynamics, validated on 29 real-world RRMM patients, identifies patient-specific baseline disease burden, tumor antigen density, and CAR-T expansion capacity as key determinants of response and relapse to BCMA/GPRC5D-targeted CAR-T, enabling virtual trial simulations to optimize dosing and patient selection.
What the study was
- Study design
- computational
- Category
- hematologic_malignancies
- Maturity
- translational
- Journal
- Clinical Pharmacology and Therapeutics
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.